Evaluation of the Efficacy of Systemic Treatments for Alopecia (ESTAA)

NCT06471114 | Unknown

• 1 other identifier: 29BRC23.0239 - ESTAA
• Study Type: observational
• Target: 250
• Locations: 1 country
• Sites: 1

Brief Summary

The aim of our study was to retrospectively assess the efficacy and safety of systemic treatments in patients with alopecia areata, by recruiting cases from the HUGO network (Hôpitaux Universitaires du Grand Ouest), a network of 5 hospitals : Brest, Nantes, Rennes, Angers and Tours.

Conditions

Alopecia Areata

Keywords

severe

Outcome Measures

Primary Outcomes (1)

• Short-term efficacy and security of systemic treatments

  Response rates including complete response or partial response or no response for each modality of treatment. and Side effects rate

  From January 2010 to December 2020

Secondary Outcomes (1)

• Long-term efficacy of systemic treatments

  From January 2010 to December 2020

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients selected from 5 university hospitals in the HUGO network (Brest, Rennes, Tours, Angers, Nantes).

You may qualify if:

• Patient with severe alopecia
• Has received at least one systemic treatment for at least 3 months (among methotrexate, intravenous or oral corticosteroid therapy, Ciclosporin, UVA/UVB phototherapy)
• Patient affiliated to a social security scheme
• Age greater than or equal to 18 years

You may not qualify if:

• Patients under legal protection (guardianship, curatorship, etc.)
• Refusal to participate
• Other cause of alopecia
• Follow-up less than 3 months
• Age under 18 years

Sponsors & Collaborators

• University Hospital, Brest: lead

Study Sites (1)

Chu Brest

Brest, 29609, France

Location

MeSH Terms

Conditions

Alopecia Areata; Lymphoma, Follicular

Condition Hierarchy (Ancestors)

Alopecia; Hypotrichosis; Hair Diseases; Skin Diseases; Skin and Connective Tissue Diseases; Lymphoma, Non-Hodgkin; Lymphoma; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 29, 2024
• First Posted: June 24, 2024
• Study Start: November 1, 2023
• Primary Completion: October 30, 2025
• Study Completion: October 30, 2025
• Last Updated: June 24, 2024

Record last verified: 2023-10

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL
• Time Frame: Data will be available beginning three years and ending fifteen years following the final study report completion
• Access Criteria: Data access requests will be reviewed by the internal committee of Brest UH. Requestors will be required to sign and complete a data access agreement

Locations

FR (1)